FDA approves Gilead's potential hepatitis C blockbuster

Gilead Sciences Inc.'s big risk is paying off. The Foster City-based drug developer (NASDAQ: GILD) won Food and Drug Administration approval Friday for its potential blockbuster hepatitis C treatment, which will cost $84,000 for a 12-week course of treatment...